Trials / Completed
CompletedNCT00692172
Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis
An Open-Label, Multi-center Study to Evaluate the Safety and Tolerability of Intramuscular Administration of Alefacept (LFA-3/IgG1 Fusion Protein) in Subjects With Chronic Plaque Psoriasis Who Have Completed Studies C99-717 or C99-712
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 175 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An extension study to evaluate safety and tolerability of up to 3 additional courses of IM alefacept in patients with chronic plaque psoriasis who have been previously treated with 1 or 2 courses of IM alefacept.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alefacept | intramuscular injection (IM) |
Timeline
- Start date
- 2001-12-01
- Primary completion
- 2004-11-01
- Completion
- 2004-11-01
- First posted
- 2008-06-06
- Last updated
- 2014-09-18
Locations
43 sites across 9 countries: United States, Belgium, Canada, Denmark, France, Germany, Netherlands, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00692172. Inclusion in this directory is not an endorsement.